Business Daily Media

The Times


.

Immuno Cure BioTech acquires Shanghai Teresa Healthcare

Integrating Electroporation Technology & DNA Vaccine Platforms

HONG KONG SAR - Media OutReach - 20 September 2022 - Immuno Cure BioTech, a clinical stage biotechnology group based in the Hong Kong Science Park specialising in DNA vaccines and immunotherapies, announced today the acquisition of 92.6% of Shanghai Teresa Healthcare, the pioneer of electroporation technology and device in China.

The transaction will be settled in cash and shares. Teresa's shareholders will swap for about 1.5% equity in Immuno Cure while the inventor of Teresa's EP technology, Professor XU Yuhong (徐宇虹), maintains her 7.4% direct equity in Teresa.

Teresa EP device delivers brief electrical pulses to promote efficient penetration of DNA vaccine through cell membrane for the enhancement of gene expression and ultimate immune responses. It is the only such device approved by National Medical Products Administration for the administration of DNA vaccine in China. Such EP technology has been an integral part of Immuno Cure's DNA vaccine delivery strategy from research to clinical stage.

Founded in 2004, Shanghai Teresa is an innovative medical device group focusing in electro immunotherapies and rehabilitation therapies. In 2005, Teresa's electroporation technology was developed to enhance the delivery of DNA medicine, based on the intellectual property generated by Shanghai Jiao Tong University under the National 863 Project. Such EP technology has been proven safe and efficacious after deployment of over 10,000 times in collaboration with more than thirty hospitals for the administration of DNA medicine in numerous human trial subjects.

Immuno Cure has two PD-1-Enhanced DNA vaccines currently in phase 1 clinical trial for prevention of COVID-19 and therapeutic cure of HIV/AIDS.

Dr JIN Xia, CEO of Immuno Cure said, "Immuno Cure has partnered with Teresa over the years in developing customised EP delivery strategy for our PD-1-Enhanced DNA vaccines, which has brought about encouraging results in clinical setting recently. I am pleased with this convergence with Teresa, which will no doubt bring our teams even closer together. Teresa will continue to operate independently while leveraging on Immuno Cure's R&D platform for the development of their next generation non-invasive EP technology for intradermal delivery strategy. Immuno Cure is committed to support the continual growth and success of Teresa."

Ms. CHEN Liye, CEO of Teresa said, "Founded on our long term collaboration, Teresa is excited to become a member of Immuno Cure Group. This move will not only provide us with a much closer R&D relationship, which is essential for our technology advancement but also offer us the financial capability to meet future needs. Teresa treasures our collaborations with other players in the field and look forward to continuing our collaborations with new and sustainable EP technology."

Professor CHEN Zhiwei, Director of AIDS Institute at the University of Hong Kong and the Principal Scientific Advisor of Immuno Cure said, "Our research and development work at the AIDS Institute and Immuno Cure has benefitted from Teresa's EP technology and their diligent collaborative effort over the past 12 years. I am pleased to see their relationship developing into an even closer tie. Look forward to the development of the next generation of EP technology for further optimisation of delivery strategy and patient experience."

Dr Percy CHENG, Chairman of Immuno Cure concludes, "This transaction offers Immuno Cure the opportunity to secure Teresa's EP technology for support of not only R&D but also the clinical administration of our PD-1-Enhanced DNA vaccines. We are pleased with Professor XU's decision to remain as our co-investor in Teresa and are optimistic in the future of EP technology in our DNA vaccine development."Hashtag: #ImmunoCureBiotech

The issuer is solely responsible for the content of this announcement.

Immuno Cure BioTech

Immuno Cure BioTech is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of vaccines and immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-Enhanced DNA vaccine and Anti-Δ42PD1 Blocking Antibody technology platforms.

To learn more about Immuno Cure BioTech, please visit

Shanghai Teresa Healthcare

Founded in 2004, Shanghai Teresa is an innovative medical device group based in Shanghai Zhangjiang Hi-Tech Park, focusing in electro immunotherapies and rehabilitation therapies.

To learn more about Shanghai Teresa Healthcare, please visit




News from Asia

Brother "Managed Print Service" Enables Businesses to Reduce Operating Costs and Enhance Efficiency with Flexible Deployment

HONG KONG SAR – Media OutReach Newswire – 5 October 2026 – Amid rising operating costs and accelerating digital transformation, many small and medium-sized enterprises (SMEs) in Hong Kong ar...

NAMAA Revolutionizes Food Delivery in the Middle East with the Launch of Future Foods and Picnic

HONG KONG SAR – Media OutReach Newswire – 5 October 2026 – NAMAA has announced the launch of Future Foods and Picnic, two new ventures that support restaurants, businesses and consumers across t...

Benchmarking Asia's Global Hubs: Hong Kong General Chamber of Commerce Unveils the Asian Cities Internationality Index 2026

Tracking 11 major cities to assess internationality, the index provides data-driven insights to shape urban policy, guide business strategy, and encourage regional exchange HONG KONG SAR – Media O...

Patience Is Being Repriced as Government Borrowing, AI And Energy Compete For Long-Term Capital: GIC CEO Lim Chow Kiat

Fifth WMI Global-Asia Family Office Summit examines portfolio resilience and next-generation readiness as WMI research identifies meaningful participation as a key marker of preparednessSINGAPORE –...

Siam Piwat to Invest US$300 Million (THB10 Billion) in ICONPHUKET, The Icon of Southern Wonders, Opening in 2029

ICONPHUKET will create a first-of-its-kind Hybrid Retail-Attraction & Entertainment Destination, featuring 12 extraordinary world-class attractions designed to captivate global aud...

Prime Supermarket Launches Fresh Quby Fruity Coin Banks PWP Collection, Developed by DTC World

Four fruit-themed Quby coin banks are being released two weeks apart at all 24 Prime Supermarket outlets until 31 December 2026. Singapore-headquartered creative merchandise company DTC World handl...

Rethinking the 10,000-Step Myth: How "Movement Snacks" Can Reclaim Energy for Hong Kong's Desk Workers

Clinical PNOE testing on Joe Wicks MBE reveals sedentary lifestyles degrade fat-burning efficiency in just 72 hoursHONG KONG SAR – Media OutReach Newswire – 5 October 2026 – For millions of busy ...

Huawei and Qualcomm Announce Broad Patent License Agreement

SHENZHEN, CHINA – Media OutReach Newswire – 5 October 2026 – Huawei and Qualcomm today announced a multi-year, broad patent license agreement that includes cross licenses to the companies' patent ...

Chubb Wealth Q4 2026 Investment Outlook: A Less Synchronized World

HONG KONG SAR – Media OutReach Newswire – 5 October 2026 – Chubb Wealth released its Q4 2026 Investment Outlook, A Less Synchronized World, highlighting a resilient but increasingly uneven global...

Thailand's LTR Visa Hits 12,000 Approvals in Four Years, Adding USD 1.28 Billion to the Economy

BANGKOK, THAILAND – Media OutReach Newswire – 5 October 2026 – The Long-Term Resident (LTR) visa has attracted 12,010 high-potential foreigners to Thailand in four years, generating approximately ...

Customer Service Is Becoming Part of the Small Business Sales and Marketing Engine

For Customer Service Week, 5-9 October, Thryv is urging small businesses to look beyond generating  enquiries and examine what happens after a custome...

Gift Cards as the gateway to agentic payments

Prepaid and stored value gives consumers the trust and control to try AI shopping agents By Blackhawk Network VP Head of ANZ Kieran Nolan For deca...

Why Data Accumulation Without Governance Undermines Sustainability Goals

In July 2026, Group 2 entities, the second cohort of Australian businesses, began their first reporting period under the mandatory climate disclosur...

Permanent $20,000 Instant Asset Write-Off Gives Small Businesses Greater Planning Certainty

The Federal Government’s decision to permanently legislate the $20,000 instant asset write-off will give eligible small businesses greater certainty...

Selling a Small Business in Australia: Understanding the Capital Gains Tax Concessions

For many Australian business owners, selling a business represents the reward for years—sometimes decades—of hard work. Unlike employees who may bu...

Australian businesses lean into global strategic partnerships (GCCs) for next wave of outsourcing

The Australian corporate landscape is undergoing a fundamental transformation in how it sources talent and innovation. While businesses have traditi...